Journal article
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
- Abstract:
-
Objectives: MAXIMISE trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of PsA.
Methods: This phase 3b, double-blind, placebo-controlled, multicentre 52-week trial included patients (≥18 years) diagnosed with PsA and classified by ClASsification criteria for Psoriatic Arthritis (CASPAR) criteria, with spinal pain visual analogue score ≥ 40/100 and Bath Ankylosing Spondylitis Disease Activity Index (...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- BMJ Publisher's website
- Journal:
- Annals of the Rheumatic Diseases Journal website
- Volume:
- 80
- Issue:
- 5
- Pages:
- 582-590
- Publication date:
- 2020-12-17
- Acceptance date:
- 2020-12-01
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1147537
- Local pid:
- pubs:1147537
- Deposit date:
- 2020-12-02
Terms of use
- Copyright holder:
- Baraliakos et al.
- Copyright date:
- 2020
- Rights statement:
- © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record